Theresa K. Leslie

Theresa K. Leslie

Auto-generated profile, based on publicly available information

Theresa K. Leslie

Department of Biology, University of York, York, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in The Journal of Physiology
Verified
Journal Article
Open access
TLTheresa K. Leslie
Theresa K. Leslie
William J BrackenburyWilliam J Brackenbury
William J Brackenbury
Cancers of epithelial origin such as breast, prostate, cervical, gastric, colon and lung cancer account for a large proportion of deaths worldwide. Better treatment of metastasis, the main cause of cancer deaths, is therefore urgently required. Several of these tumours have been shown to have an abnormally high concentration of Na+ ([Na+]) and emerging evidence points to this accumulation being due to elevated intracellular [Na+]. This poses intriguing questions about the cellular mechanisms underlying Na+ dysregulation in cancer, and its pathophysiological significance. Elevated intracellular [Na+] may be due to alterations in activity of the Na+/K+‐ATPase, and/or increased influx via Na+ channels and Na+‐linked transporters. Maintenance of the electrochemical Na+ gradient across the plasma membrane is vital to power many cellular processes that are highly active in cancer cells, including glucose and glutamine import. Na+ channels are also upregulated in cancer cells, which in turn promotes tumour growth and metastasis. For example, ENaC and ASICs are overexpressed in cancers, increasing invasion and proliferation. In addition, voltage‐gated Na+ channels are also upregulated in a range of tumour types, where they promote metastatic cell behaviours via various mechanisms, including membrane potential depolarisation and altered pH regulation. Together, recent findings relating to elevated Na+ in the tumour microenvironment and how this may be regulated by several classes of Na+ channels provide a link between altered Na+ handling and poor clinical outcome. There are new opportunities to leverage this altered Na+ microenvironment for therapeutic benefit, as exemplified by several ongoing clinical trials. image

25 July 2024 in Oncogene
Verified
Journal Article
Open access
PDF file
TLTheresa K. Leslie
Theresa K. Leslie
ATAurelien Tripp
Aurelien Tripp
AJAndrew James
Andrew James
SFScott P. Fraser
Scott P. Fraser
MNMichaela Nelson
Michaela Nelson
William J BrackenburyWilliam J Brackenbury
William J Brackenbury
Solid tumours have abnormally high intracellular [Na+]. The activity of various Na+ channels may underlie this Na+ accumulation. Voltage-gated Na+ channels (VGSCs) have been shown to be functionally active in cancer cell lines, where they promote invasion. However, the mechanisms involved, and clinical relevance, are incompletely understood. Here, we show that protein expression of the Nav1.5 VGSC subtype strongly correlates with increased metastasis and shortened cancer-specific survival in breast cancer patients. In addition, VGSCs are functionally active in patient-derived breast tumour cells, cell lines, and cancer-associated fibroblasts. Knockdown of Nav1.5 in a mouse model of breast cancer suppresses expression of invasion-regulating genes. Nav1.5 activity increases ATP demand and glycolysis in breast cancer cells, likely by upregulating activity of the Na+/K+ ATPase, thus promoting H+ production and extracellular acidification. The pH of murine xenograft tumours is lower at the periphery than in the core, in regions of higher proliferation and lower apoptosis. In turn, acidic extracellular pH elevates persistent Na+ influx through Nav1.5 into breast cancer cells. Together, these findings show positive feedback between extracellular acidification and the movement of Na+ into cancer cells which can facilitate invasion. These results highlight the clinical significance of Nav1.5 activity as a potentiator of breast cancer metastasis and provide further evidence supporting the use of VGSC inhibitors in cancer treatment.

2 October 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
TLTheresa K. Leslie
Theresa K. Leslie
LBLotte Brückner
Lotte Brückner
SCSangeeta Chawla
Sangeeta Chawla
William J BrackenburyWilliam J Brackenbury
William J Brackenbury
Eslicarbazepine acetate (ESL) is a dibenzazepine anticonvulsant approved as adjunctive treatment for partial-onset epileptic seizures. Following first pass hydrolysis of ESL, S-licarbazepine (S-Lic) represents around 95% of circulating active metabolites. S-Lic is the main enantiomer responsible for anticonvulsant activity and this is proposed to be through the blockade of voltage-gated Na+ channels (VGSCs). ESL and S-Lic both have a voltage-dependent inhibitory effect on the Na+ current in N1E-115 neuroblastoma cells expressing neuronal VGSC subtypes including Nav1.1, Nav1.2, Nav1.3, Nav1.6, and Nav1.7. ESL has not been associated with cardiotoxicity in healthy volunteers, although a prolongation of the electrocardiographic PR interval has been observed, suggesting that ESL may also inhibit cardiac Nav1.5 isoform. However, this has not previously been studied. Here, we investigated the electrophysiological effects of ESL and S-Lic on Nav1.5 using whole-cell patch clamp recording. We interrogated two model systems: (1) MDA-MB-231 metastatic breast carcinoma cells, which endogenously express the “neonatal” Nav1.5 splice variant, and (2) HEK-293 cells stably over-expressing the “adult” Nav1.5 splice variant. We show that both ESL and S-Lic inhibit transient and persistent Na+ current, hyperpolarise the voltage-dependence of fast inactivation, and slow the recovery from channel inactivation. These findings highlight, for the first time, the potent inhibitory effects of ESL and S-Lic on the Nav1.5 isoform, suggesting a possible explanation for the prolonged PR interval observed in patients on ESL treatment. Given that numerous cancer cells have also been shown to express Nav1.5, and that VGSCs potentiate invasion and metastasis, this study also paves the way for future investigations into ESL and S-Lic as potential invasion inhibitors.

15 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
AJAndrew James
Andrew James
TLTheresa K Leslie
Theresa K Leslie
JKJoshua D Kaggie
Joshua D Kaggie
LWLaura Wiggins
Laura Wiggins
LPLewis Patten
Lewis Patten
William J BrackenburyWilliam J Brackenbury
William J Brackenbury
Breast cancer is the leading cause of cancer-related death in women worldwide. Development of novel noninvasive diagnostic and predictive pathophysiological biomarkers would represent a significant clinical improvement. Here, we explored the utility of non-invasive 23 Na MRI to profile tumour physiology using preclinical mouse models of breast cancer. We establish that tissue Na + concentration ([Na + ]) is elevated vs non-tumour regions across multiple different tumour models. Ex vivo SBFI fluorescence imaging corroborated that this elevation in tumour [Na + ] is due to increased intracellular [Na + ]. Effective treatment with cytotoxic chemotherapy reduced tumour tissue [Na + ], but was not detected by 1 H diffusion-weighted imaging (DWI). Moreover, combining 23 Na MRI and DWI measurements enabled superior classification accuracy of tumour vs non-tumour regions compared to either parameter alone. Quantification of breast tumour tissue [Na + ] using 23 Na MRI thus represents a novel, accurate, non-invasive diagnostic and predictive imaging biomarker.

25 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
TLTheresa K. Leslie
Theresa K. Leslie
LBLotte Brückner
Lotte Brückner
SCSangeeta Chawla
Sangeeta Chawla
William J BrackenburyWilliam J Brackenbury
William J Brackenbury
Eslicarbazepine acetate (ESL) is a dibenzazepine anticonvulsant approved as adjunctive treatment for partial-onset epileptic seizures. Following first pass hydrolysis of ESL, S-licarbazepine (S-Lic) represents around 95 % of circulating active metabolites. S-Lic is the main enantiomer responsible for anticonvulsant activity and this is proposed to be through the blockade of voltage-gated Na + channels (VGSCs). ESL and S-Lic both have a voltage-dependent inhibitory effect on the Na + current in N1E-115 neuroblastoma cells expressing neuronal VGSC subtypes including Na v 1.1, Na v 1.2, Na v 1.3, Na v 1.6 and Na v 1.7. ESL has not been associated with cardiotoxicity in healthy volunteers, although a prolongation of the electrocardiographic PR interval has been observed, suggesting that ESL may also inhibit cardiac Na v 1.5 isoform. However, this has not previously been studied. Here, we investigated the electrophysiological effects of ESL and S-Lic on Na v 1.5 using whole-cell patch clamp recording. We interrogated two model systems: (1) MDA-MB-231 metastatic breast carcinoma cells, which endogenously express the ‘neonatal’ Na v 1.5 splice variant, and (2) HEK-293 cells stably over-expressing the ‘adult’ Na v 1.5 splice variant. We show that both ESL and S-Lic inhibit transient and persistent Na + current, hyperpolarise the voltage-dependence of fast inactivation, and slow the recovery from channel inactivation. These findings highlight, for the first time, the potent inhibitory effects of ESL and S-Lic on the Na v 1.5 isoform, suggesting a possible explanation for the prolonged PR interval observed in patients on ESL treatment. Given that numerous cancer cells have also been shown to express Na v 1.5, and that VGSCs potentiate invasion and metastasis, this study also paves the way for future investigations into ESL and S-Lic as potential invasion inhibitors.